The grocery store formerly known as Steve’s 9th Street Supermarket in Park Slope has a new occupant. K Slope Market, a full-service supermarket and member of the Key Food Cooperative, opened its doors ...

This content was first published in Golf Journal, a quarterly print and monthly digital publication exclusively for USGA Members. To be among the first to receive Golf Journal and to learn how you can ...

Once again, Israeli bombs rained down on Gaza. The latest wave of strikes killed more than 100 people, mostly women and children, according to health authorities. The bombardment marked the deadliest ...

Crew members on flotilla vessel Conscience after intercepted by Israeli forces A new flotilla heading for the Gaza Strip with food and medical supplies on board has been intercepted by Israeli forces.

The North American Aerospace Defense Command (NORAD) scrambled fighter jets on Wednesday to identify and intercept four Russian military planes off Alaska, the US and Canadian defense organization ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

A federal judge in San Francisco on Wednesday temporarily blocked a federal administrative subpoena aimed at unmasking Instagram accounts that named and shamed a Border Patrol agent who was part of ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...